16 / 17
Page 55
allied
academies
Journal of Current Pediatric Research | Volume: 23
March 14-15, 2019 | London, UK
International Conference on
Pediatrics & Neonatal Healthcare
Background: Neonatal hypoxic-ischemic encephalopathy (HIE)
is a severe disease, and there’s no effective treatment for severe
HIE. In recent years, a large number of animal experiments
have confirmed that stem cell transplantation has shown great
potential in regenerative medicine, such as in the treatment
of hypoxic-ischemic brain damage (HIBD)[1]. The most widely
used are human umbilical cord-derived mesenchymal stem
cells (UC-MSCs) and mononuclear cells from cord blood (CB-
MNCs) because of their ample availability[2, 3]. However, there
are still many problems on their applications, for instance, it is
unclear which types of cells is more effective for HIE? Methods:
HIBD was produced using Rice-Vannucci method postnatal day
7 (P7) rats[4]. Briefly, after a 30min rest, the rats were exposed
to a hypoxic environment of 8% at 37℃ for 2 hours. 24 hours
later, UC-MSCs and UCB-MNCs labeled with PKH26 and Hu-Nu
respectively were transplanted into the lateral ventricle of rats.
A control group underwent ligation of the left carotid artery
and hypoxia in the same manner,but received an equivalent
volume of PBS alone. The sham group underwent neither left
carotid artery ligation nor hypoxia. At 24 h after transplantation,
the number of apoptotic cells was detected by TUNEL. We
monitor the migration of transplanted cells, and the expression
of myelin basic protein (MBP) and glial fibrillary acidic protein
(GFAP) at 2 weeks post-transplantation respectively. The Morris
water maze was used to assess animal learning abilities at 3
weeks post-transplantation. Results: On the three day after
transplantation, UC-MSCs and CB-MNCs were mainly located
in cerebral cortex and corpus callosum around the hypoxic-
ischemic region of the ipsilateral hemisphere. However hardly
any labeled cells were found after 2weeks post-transplantation.
Treatment with UC-MSCs and CB-MNCs did not affect cortical
neuronal apoptosis, but was associated with reduced neuronal
apoptosis in the striatumon the second day after HIBD (P<0.05).
After 2 weeks post-transplantation, compared to the sham
group, levels of GFAP labeling in control groupwere upregulated
significantly in the cerebral cortex and striatum (P<0.05). CB-
MNCs inhibited up-regulation of GFAP in the striatum (P<0.05),
while UC-MSCs inhibited this in both the striatum (P<0.01) and
the cortex (P<0.05). When compared to the control group, MBP
expression levels in the CB-MNCs groupwere upregulated in the
cerebral cortex and corpus callosum (P<0.05). However, there
were no significant differences between the UC-MSCs group
and the control group (P>0.05). The rats in the transplanted
groups showed significant improvement in escape latency to
find the submerged platform than those of rats in the control
group (P<0.01), repeated measures ANOVA). In the probe trial,
control rats exhibited significant spatial memory deficits. A one-
way ANOVA revealed that the number of times animals crossed
the platform location decreased in the control and transplanted
groups belowshamgroup levels, though the transplanted group
animals crossed more than the control group animals (P<0.05).
Furthermore, there were no statistically significant differences
between the transplanted groups across either stage of testing
(training trials or probe trial) (P>0.05). Conclusions: Both UC-
MSCs and CB-MNCs could have a beneficial effect on recovery
of neurological function in HIBD rats, although the possible
mechanisms may be different between the two groups. Our
data suggest that UC-MSCs and CB-MNCs could serve as a
potential approach for the treatment of neonatal HIE and
develop a guidance in clinical cellular therapeutics.
e:
chenjuan2000@163.comUmbilical cord mesenchymal stem cells and umbilical cord blood mononuclear cells improve neonatal rat
memory after hypoxia-ischemia
1Juan Chen, 1Jie Zhang, 1Yi Qu, 1Dezhi Mu, 2Chao Yang and 2Qiang Chen
1West China Second University Hospital Sichuan University Chengdu, China
2Sichuan Neo-life Stem Cell Biotech Inc., China
Curr Pediatr Res, Volume 23
DOI: 10.4066/0971-9032-C1-012